Table 1. Clinical-pathological characteristics of patients analyzed for TAGLN2 mRNA expression in institutional and TCGA LGG cohorts.
| Clinical Factor | Institutional Cohort TAGLN2 Expression | TCGA Cohort TAGLN2 Expression | ||||
|---|---|---|---|---|---|---|
| TAGLN2 mRNA | Above median (n=29) |
Below median (n=29) |
P | Above median (n=258) |
Below median (n=258) |
P |
| Age | 42 | 42 | 0.539 | 45 | 38 | <0.001 |
| Gender | 0.038 | 0.182 | ||||
| Female | 4 (13.8%) | 12 (41.4) | 101 (39/1%) | 100 (38.8%) | ||
| Male | 25 (86.2%) | 17 (58.6%) | 134 (51.9%) | 122 (47.3%) | ||
| Unknown | N/A | N/A | 23 (8.9%) | 36 (14.0%) | ||
| Histology | 0.278 | <0.001 | ||||
| Astrocytoma | 7 (24.1%) | 4 (13.8%) | 106 (41.1%) | 63 (24.4%) | ||
| Mixed | 13 (44.8%) | 13 (44.8%) | 56 (21.7%) | 58 (22.5%) | ||
| Oligodendroglioma | 7 (24.1%) | 12 (41.4%) | 73 (28.3%) | 101 (39.1%) | ||
| Unknown | 2 (6.9%) | N/A | ||||
| Grade | 0.263 | <0.001 | ||||
| II | 12 (41.4%) | 7 (24.1%) | 92 (35.7%) | 124 (48.1%) | ||
| III | 17 (58.6%) | 22 (75.9%) | 143 (55.4%) | 98 (38.0%) | ||
| Unknown | N/A | N/A | 23 (8.9%) | 36 (14.0%) | ||
| IDH1/2 Mutation Status | 0.102 | <0.001 | ||||
| IDH1/2 Mutant | 23 (79.3%) | 28 (96.6%) | 168 (65.1%) | 251 (97.3%) | ||
| IDH1/2 WT | 6 (20.7%) | 1 (3.4%) | 88 (34.1%) | 6 (2.3%) | ||
| Unknown | N/A | N/A | 2 (0.8%) | 1 (0.4%) | ||
| 1p/19q Status | 0.114 | 0.005 | ||||
| Co-deleted | 11 (37.9%) | 18 (62.1%) | 69 (26.7%) | 100 (38.8%) | ||
| Non-co-deleted | 18 (62.1%) | 11 (37.9%) | 189 (73.3%) | 158 (61.2%) | ||